Introduction: The brain-derived neurotrophic factor (BDNF) Val66Met variant and HMG-COA reductase inhibitors (statins) have been implicated in insulin resistance with a possible increased risk of diabetes. We sought to determine the effect of the BDNF Met variant and statin medication use on insulin resistance in schizophrenia and bipolar disorder using the homeostasis model assessment of insulin resistance (HOMA-IR). Methods: A cross-sectional design was used and patients with diabetes or on any medications affecting glucose regulation were excluded. Associations between insulin resistance and genotype were then analyzed by ANOVA and regression analysis. Subjects were grouped by BDNF genotype as well as presence of statin. Results: Two hundred fi fty-two subjects with a mean age of 44 years were included. The group was 53% male and 41% had a diagnosis of bipolar disorder; 78% and 19% were receiving atypical antipsychotics (AAPs) and statin medications, respectively. Analysis showed schizophrenia subjects with the BDNF met allele as well as schizophrenia subjects with both the BDNF met allele and were receiving a statin had signifi cantly higher HOMA-IR values compared to the other groups ( p = 0.046 and p = 0.016, respectively). Conclusions: Our results suggest that in the metabolically high-risk population of schizophrenia the BDNF met allele alone and in combination with statin medications is associated with higher insulin resistance values. This was not seen in the bipolar population. Further validation of these associations remains necessary. Clin Trans Sci 2012; Volume 5: 486-490
Introduction
Antipsychotic use is a common treatment for patients with schizophrenia and bipolar disorder. With the advent of the atypical antipsychotics (AAPs), the rates of undesirable metabolic complications like weight gain and type II diabetes mellitus has increased within these patient populations. 1 In addition, lifestyle habits and pharmacogenetics have been touted as having a role in developing type II diabetes within these populations. 2, 3 Although several pharmacogenetic variants have been implicated in the metabolic dysregulations seen with AAP use, 4, 5 one that is currently emerging within the general population is the brainderived neurotrophic factor (BDNF). 6, 7 Th e BDNF Val66Met (196 G/A) variant has been implicated in both schizophrenia and bipolar disorder due to its role in neuronal health, development, and function. 8, 9 Pharmacogenetically, a BDNF gene variant identifi ed at codon 66 results in a methionine (Met) substitution for valine (Val) and results in a drastic impairment of BDNF packaging and distribution. 10 In animal and human models within the general population, the Met allele is associated with an increased risk of diabetes and insulin resistance through altered regulation of glucose metabolism and feeding habits.
11 Given the strong relationship between mental illness, AAP treatment, and glucose regulation, BDNF genetic variability may mediate development of type 2 diabetes (T2DM) in a large percentage of AAP treated patients. However, the relationship between this variant and glucose dysregulation seen in schizophrenia and bipolar disorder has not been studied. Although all metabolic complications carry a certain degree of risk, development of T2DM adds additional risks. Th erefore, these patients require careful clinical monitoring.
It is standard of practice to treat cholesterol abnormalities with hydroxymethylglutaryl CoA reductase inhibitors also known as "statins. " Th ese medications have recently been implicated in increasing the risk of diabetes and insulin resistance 12 and also have eff ects on circulating BDNF and the cleavage of pro-BDNF in certain populations. 13, 14 Th eir cautious use in populations at increased risk for diabetes like that of schizophrenia and bipolar disorder has been advised, however, work delineating the true extent of this risk in those with a serious mental illness is unknown.
This investigation sought to determine the relationship between the BDNF 66 Met allele and insulin resistance in schizophrenia and bipolar patients. In addition, we determined the relationship between statin medication use, BDNF 66Met allele carriers and insulin resistance in this same cohort.
Materials and Methods

Subjects and data collection
Participants were recruited from Southeastern Michigan mental health clinics using the following study inclusion criteria: (i) Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) diagnosis of schizophrenia, schizophreniform disorder, schizoaff ective disorder, or bipolar disorder, (ii) 18-90 years old, and (iii) no medication changes in the prior 6 months. Participants were excluded if they were unable to give informed consent, had diabetes before starting antipsychotic treatment, had any condition signifi cantly aff ecting glucose and insulin measures or had an active substance abuse diagnosis. Th e protocol was approved by the University of Michigan Institutional Review Boards. 15 was calculated for each patient using the following formula:
HOMA-IR = [fasting insulin (pIU/mL) × fasting blood glucose (mmol/L)]/22.5
Although various thresholds for insulin resistance have been identifi ed, 16 a HOMA-IR above 2.6 was used as a threshold for insulin resistance. 17 Subjects were excluded from this analysis if they had a documented diabetes diagnosis or were receiving diabetes treatment since treatment for diabetes would artifi cially lower insulin resistance values giving a false negative fi nding using the HOMA-IR.
Each patient was assessed for metabolic syndrome using the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP-III Criteria).
18 Structured Clinical Interview for DSM Diagnoses (SCID) conducted by a trained research assistant and medical record review was used to confi rm diagnoses. Participant complete medication histories were collected by medical record and patient interview. Social histories were also completed. Subjects were segregated to account for metabolic side eff ects diff erences for a given antipsychotic as follows: (1) olanzapine or clozapine, (2) quetiapine, risperidone, paliperidone or iloperidone, and (3) all other antipsychotics or no antipsychotic.
Analytical methods
DNA was extracted from whole blood 19 and for genotyped for the BDNF Val66Met variant (DBSNP rs6265) using Pyrosequencing. 20 Pyrosequencing primers were designed using Pyrosequencing Nucleotide Polymorphism (SNP) primer design version 1.01 soft ware ( http://www.pyrosequencing.com ). Conditions for the specifi c assay are available upon request.
Statistical analysis
Due to the anticipated low-genotype frequency of the BDNF 66MetMet genotype, the statistical analysis was performed by forming two groups: ValVal genotype and those carrying a Met allele (ValMet or MetMet genotypes). For our second aim, the genotype groups were stratifi ed by presence or absence of statin use. Th e primary group of interest within this second aim was those subjects taking statins and carrying a 66 Met Allele compared to all others. A power analysis showed that to detect a clinically meaningful diff erence of 1.0 in HOMA-IR with a power of 80% a sample size approximately 56 was needed. Student t -tests and chisquare analyses were used for baseline demographics comparisons based on the two genotype groupings. ANOVA examined the relationship of genotype, statins, and HOMA-IR. Regression analysis was performed to analyze the relationship between BDNF genotype status and HOMA-IR, whereas controlling for variables we found to signifi cantly eff ect HOMA-IR. HOMA-IR was used as the dependent variable while the genotype-based groups and the variables aff ecting HOMA-IR (detailed in results) were used as the independent variables for each aim stated above. We then analyzed based on each diagnosis given the diff erences in pathogenesis and medication use for these two diseases. All analyses utilized the JMP 9.0 statistical program. A p -value < 0.05 with a 95% confi dence interval was considered signifi cant.
Results
Aft er excluding based on the criteria above (diagnosis of diabetes or current diabetes treatment), our fi nal sample size for data analysis was 252 (148 with a schizophrenia spectrum diagnosis and 104 with a bipolar diagnosis). See Table 1 for demographic characteristics. Th e BDNF Val66Met genotypes were in Hardy Weinberg Equilibrium for the entire cohort as well as for each diagnosis spectrum (all p > 0.26). Eight participants were unable to be genotyped.
Comparisons of all subject found a few signifi cant diff erences. Th e schizophrenia cohort had a higher percentage of male and African American subjects compared to the bipolar cohort ( p < 0.05 for both), there were more schizophrenia subjects receiving AAPs ( p = 0.02), diff erences in the percentage of subjects who were current smokers ( p = 0.01) and diff erences in lipid levels between the two cohorts (Total Cholesterol: p = 0.003; HDL: p = 0.01; LDL: p = 0.02). See Table 1 for percentage comparisons between the two groups.
Preliminary analysis found that in the combined sample, the Met allele carriers were older (46 vs. 43 years old, p = 0.043), less likely to be African Americans (5% vs. 26%, p = 0.005), and had higher AAP use (89% vs. 73%, p = 0.010). Th ere were no signifi cant diff erences for the schizophrenia or bipolar groups based on genotype No signifi cant relationship was found between the BDNF 66 Met allele and HOMA-IR for the whole group ( p = 0.3). However when segregated by diagnosis, we found a signifi cant eff ect of the BDNF 66Met allele on HOMA-IR in the schizophrenia sample where subjects carrying the Met allele had higher HOMA-IRs ( p = 0.046). No relationship was found for the bipolar group (analysis in Table 2 , Figure 1 ).
Th ere were no eff ects of statin medications on BDNF 66Met allele carriers in the entire cohort ( p = 0.2). However, the schizophrenia subjects currently taking statin medications and carrying the Met allele had signifi cantly higher HOMA-IRs compared to all other schizophrenia subjects ( p = 0.016). No relationship was found in the bipolar cohort (analysis in Table 2 ).
In addition to the previous analysis, a linear regression was performed for each dependent variable (e.g., BDNF and statin status) controlling for age, race, AAP use, BMI and metabolic syndrome. In the combined sample, there was a signifi cant interaction between BMI and BDNF 66Met carriers on HOMA-IR (f[1,1] = 3.90, p = 0.049), where those with this allele, had higher levels of insulin resistance and similar BMIs compared to the Val/Val genotype groups. Th is analysis yielded no signifi cant results for the bipolar sample. Within the schizophrenia subset, the eff ect of the BDNF 66Met allele on HOMA-IR was signifi cant by itself (f[11,135] = 4.80, p = 0.030) as well as 66Met's interaction with BMI on HOMA-IR (f(1,1) = 9.04, p = 0.0032). Finally, only the interaction between BMI and genotype was seen in the schizophrenia sample when the analysis was stratifi ed by statin use (f[1,1] = 6.26, p = 0.037), where those with the 66Met allele receiving a statin also had higher levels of insulin resistance at comparable BMIs.
Discussion
For this study, we found a signifi cant relationship between BMI, the BDNF 66 Met allele and insulin resistance in a schizophrenia population primarily treated with AAPs. Our study showed that BDNF pharmacogenetics may not be the same across diff erent populations prescribed AAPs or statins with the lack of a relationship seen in the combined and bipolar groups. Th is may suggest glucose regulation is more dependent on genetic factors like BDNF within schizophrenia. Of note, is that within our samples, the HOMA-IR values are substantially higher than general population studies, which is not surprising given the rising incidence of diabetes and metabolic syndrome. Studies in other populations have HOMA-IR averages of 1.8-2.9 whereas our average was much higher at 5.51 and 5.91 ( Table 1 ) for the schizophrenia and bipolar samples, respectively. 21, 22 Contributing to the elevated HOMA-IR may be high AAP use (78% overall) with the majority being AAPs with strong metabolic side eff ect profi les. Although not statistically signifi cant, schizophrenia subjects on clozapine, olanzapine, risperidone, paliperidone or quetiapine (68%) had a mean HOMA-IR of 5.8 versus those on ziprasidone, aripiprazole or 1st generation antipsychotics with a HOMA-IR of 5.0 ( p = 0.25) which is consistent with the literature. 23 Poor diet and a lack of activity could also be contributors to these high HOMA-IR values. Furthermore, for the combined sample, 80% had a HOMA-IR higher than a suggested threshold of 2.6 for insulin resistance.
Our study contradicts previous reports showing no association between the BDNF Val66Met polymorphism and HOMA-IR in the diabetic population 6 as we found a signifi cant association between BMI, the BDNF 66Met allele and insulin resistance within our schizophrenia sample. Th us, the BDNF Val66Met variant which has been studied for its psychiatric and cognitive eff ects 8, 24, 25 may also impact insulin resistance risk within schizophrenia, but perhaps not within other populations that uses AAPs. BMI and HOMA-IR are easily measureable clinical variables that may represent risk factors in schizophrenia, along with the BDNF Val66Met genotype to help predict greatest insulin resistance risk. Subjects may then be targeted for specifi c interventions related to insulin resistance to prevent the development of diabetes and its detrimental comorbidities and cost. Although the bipolar sample did not show a correlation with the BDNF 66Met variant, their high insulin resistance values suggest that they should be studied further in order to determine personalized approaches to diabetes risk. Statin medication use within the general population is becoming more controversial. We hypothesized that in subjects with the BDNF 66Met allele, statin use may result in greater insulin resistance. Based on our analysis, we found a signifi cant relationship in schizophrenia patients taking statins and carrying the 66Met allele resulting in a HOMA-IR measure about 1.5× higher than those patients either with the Val allele taking statins or those regardless of BDNF genotype not taking statins ( Table 2 ) . Also, the combination of the 66Met allele and statin use resulted in a HOMA-IR value more than 1.2 times higher than those patients carrying the 66Met allele alone. Th is was not seen in the bipolar population. Aft er controlling for age, race, AAP use, BMI and metabolic syndrome, these relationships remained ( p = 0.0032) suggesting that at any given BMI, schizophrenia BDNF 66Met allele carriers receiving a statin medication have signifi cantly higher HOMA-IR values. Th e combined eff ect of statin use and the BDNF 66Met allele on HOMA-IR within this population could be a result of increased proteolytic cleavage (induced by statins) of the altered form of BDNF dictated by the Met variant whereas ValVal schizophrenia patients are unaff ected by this increased cleavage since they are not producing the altered form of the BDNF protein. 10, 13 Again, with further validation future personalized medicine approachs in schizophrenia could be developed when treating hyperlipidemia. Figure 1 depicts the diff ering HOMA-IR trends between the groups as more insulin resistance risk factors (e.g., BDNF Val66Met polymorphism and statins) are added together. Originally, we hypothesized that BDNF's pharmacogenetic eff ects and statins would be the same on both populations. Th e diff erent trends could be a result of diff ering baseline characteristics between the groups (gender, AAP use, lipid levels, etc.) that could not be fully controlled during analysis, pathophysiologic processes of the diseases or diff erences in baseline diabetes risk. Also, it may be possible that the BDNF protein may not be a major contributor to insulin resistance in the bipolar population and thus, the hypothesis of increased BDNF cleavage we proposed for the schizophrenia population would not have the same eff ect. Finally, although the mechanism for statin-induced insulin resistance has not been fully elucidated, diff erences in transporter expression between schizophrenia and bipolar patients could be a future line of investigation into the diff erences seen within our study. 26 ,27 One major study limitation is that BDNF levels were not measured, however to date, the BDNF Val66Met has not been well correlated to BDNF levels. 28 Another limitation is use of a the HOMA-IR to assess insulin resistance, however, this measurement correlates well with more invasive measures of insulin resistance such as the frequently sampled IV glucose tolerance test. 29, 30 Th e cross-sectional design of our study only gives us a snapshot of insulin resistance and needs replication in order to confi rm our results. Our study population was also not drug naïve and polypharmacy was fairly common in regards to overall number of medications, making it diffi cult to confi rm the interaction of the BDNF gene, AAPs and statins within the mental illness. Our candidate gene drive study only looked at the BDNF Val66Met polymorphism because other BDNF polymorphisms have not been studied in insulin resistance in the literature. However, possible associations with other variants cannot be ruled out. Lastly, we did not control for multiple comparisons, however, our most signifi cant result in the schizophrenia population would sustain the more stringent multiple testing signifi cance level of 0.01.
Conclusion
Overall our cross-sectional study of schizophrenia and bipolar patients receiving antipsychotic treatment showed that in schizophrenia subjects, insulin resistance is associated with the BDNF 66Met allele, statin medications and BMI. No association was found for the bipolar disorder subjects. Although further validation is needed, the BDNF Val66Met variant, thought to be promising in predicting insulin resistance and glucose dysregulation, may play a role in predicting risk of developing insulin resistance and subsequently diabetes from AAP use in the schizophrenia population. Th is work helps to target genes of interest which can be followed up in future investigations, focusing on personalized medicine for those with schizophrenia.
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